Calliditas Therapeutics AB

Equities

CALTX

SE0010441584

Pharmaceuticals

Real-time Estimate Cboe Europe 14:11:03 25/06/2024 BST 5-day change 1st Jan Change
205.1 SEK -0.24% Intraday chart for Calliditas Therapeutics AB +0.29% +61.45%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Calliditas Therapeutics Gets US Patent for Cancer Treatment Candidate MT
Calliditas Therapeutics Secures US Patent for Cancer Treatment Inhibitor MT
Calliditas Therapeutics AB Provides Setanaxib Patent Update CI
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading MT
Tech Firms Lead European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading MT
Citigroup Downgrades Calliditas Therapeutics to Neutral From Buy, Price Target at $39 MT
Calliditas Partner Secures European Panel Backing for Rare Kidney Disease Treatment MT
Calliditas Therapeutics Receives Positive Opinion for Kinpeygo Marketing Authorization in Europe MT
Calliditas Partner Stada Receives Positive Chmp Opinion Recommending Full Approval for Kinpeygo[®] for the Treatment of Iga Nephropathy CI
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading MT
Transcript : Calliditas Therapeutics AB - Special Call
Asahi Kasei Offering to Buy Calliditas Therapeutics for SEK11.8 Billion MT
Health Care Stocks Post Broad Decline -- Health Care Roundup DJ
Sector Update: Health Care Stocks Fall Late Afternoon MT
Top Midday Gainers MT
HC Wainwright Downgrades Calliditas Therapeutics to Neutral From Buy, Cuts Price Target to $39 From $45 MT
Stifel Downgrades Calliditas Therapeutics to Hold From Buy, Cuts Price Target to $40 From $55 MT
European Equities Traded in the US as American Depositary Receipts Open Week Lower in Tuesday Trading MT
Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday MT
Traders Cautious Ahead of Friday's Inflation Report, Stifling US Equity Futures Pre-Bell MT
Top Premarket Gainers MT
Calliditas Therapeutics' Board Urges Shareholders to Embrace $1.06 Billion Buyout Offer MT
European shares waver as euro zone consumers lower inflation expectation RE
Chart Calliditas Therapeutics AB
More charts
Calliditas Therapeutics AB, formerly Pharmalink AB, is a Sweden-based specialty pharmaceutical company. It is focused on the development and commercialization of its product candidate Nefecon, a treatment for patients with inflammatory kidney disease (IgA nephropathy) who are at risk of progressing to renal failure. Nefecon is derived from the TARGIT technology, in which the capsule containing the active drug substance is coated in a way that the capsule remains intact as it passes through the stomach and intestine until it reaches the lower small intestine, where the release of content takes place. Nefeco combines time lag effect with a concentrated release of the active substance budesonide, within a designated target area.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
205.6 SEK
Average target price
221.2 SEK
Spread / Average Target
+7.61%
Consensus
  1. Stock Market
  2. Equities
  3. CALTX Stock
  4. News Calliditas Therapeutics AB
  5. Sector Update: Health Care Stocks Fall Late Afternoon